Open Orphan is a niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands. Open Orphan is led by a management team with deep industry and financial experience. Open Orphan (ORPH) is quoted on both the AIM and Euronext Growth markets.
Open Orphan
Niche CRO pharmaceutical services company
Company information
Company:
Private
Fund:
EIS Portfolio Service
Sector:
Biotech, Business services, Medical, Pharma
Status:
Exited
Investment Date:
10/2015
You might also be interested in...
Clinical stage biotech company with a focus on the prevention of life-threatening infections
Developer of novel aptamers for research, diagnostic and therapeutic purposes
Integrated technologies and services business enabling the delivery of genomic medicine